An SGLT inhibitor can activate AMPK phosphorylation and inhibit the mammalian target of rapamycin (mTOR) phosphorylation, thereby improving hepatic steatosis (Luo et al., 2021a). This evidence concerns the gene MTOR and Hepatic steatosis.